Key Points
- CEO Eric Keller purchased 20,800 shares of Retension Pharmaceuticals at an average price of $12.00 per share, investing a total of $249,600.
- Following the transaction, Keller owned 423,377 shares valued at approximately $5.08 million, representing a 5.17% increase in his holdings.
- RTSN opened at $11.63, within its 52-week range of $9.66 to $12.50. Retension is a clinical-stage biopharmaceutical company developing RTN-001, an oral PDE-5 inhibitor for hypertension and cardiovascular diseases.
Retension Pharmaceuticals, Inc. (NASDAQ:RTSN - Get Free Report) Director Franklin Berger bought 10,000 shares of the stock in a transaction that occurred on Tuesday, October 13th. The stock was purchased at an average price of $12.00 per share, for a total transaction of $120,000.00. Following the completion of the purchase, the director directly owned 10,000 shares in the company, valued at $120,000. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Retension Pharmaceuticals Stock Performance
Shares of RTSN opened at $11.63 on Wednesday. Retension Pharmaceuticals, Inc. has a one year low of $9.66 and a one year high of $12.50.
Retension Pharmaceuticals Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
